Literature DB >> 33608691

Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells 'off the shelf'?

Amanda M DiNofia1,2, Stephan A Grupp3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33608691     DOI： 10.1038/s41571-021-00485-1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  4 in total

Review 1.  Engineered cellular immunotherapies in cancer and beyond.

Authors:  Amanda V Finck; Tatiana Blanchard; Christopher P Roselle; Giulia Golinelli; Carl H June
Journal:  Nat Med       Date:  2022-04-19       Impact factor: 87.241

Review 2.  Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.

Authors:  Ratchapong Netsrithong; Methichit Wattanapanitch
Journal:  Front Immunol       Date:  2021-09-28       Impact factor: 7.561

Review 3.  Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

Review 4.  Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies.

Authors:  Yan-Ruide Li; Zachary Spencer Dunn; Yang Zhou; Derek Lee; Lili Yang
Journal:  Cells       Date:  2021-12-10       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.